Howe & Rusling’s Fulgent Genetics FLGT Stock Holding History

Howe & Rusling’s Portfolio FLGT Stock Details FLGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-35	Closed	-$2K	–	1094
2022 Q1	$2K	Hold	35	–	–	﹤0.01%	853
2021 Q4	$4K	Buy	+35	New	+$3.08K	﹤0.01%	724

Other funds holding FLGT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Howe & Rusling's FLGT Position: Q2 2022 in Review

Howe & Rusling sold out of Fulgent Genetics (FLGT) in Q2 2022, closing a stake of 35 shares — an estimated $2K sold.

Howe & Rusling first reported a position in FLGT in Q4 2021 and held it in 2 quarters. The position peaked at $4K in Q4 2021. 262 funds tracked by Wall St. Rank hold FLGT as of Q2 2022.

Howe & Rusling reported no remaining Fulgent Genetics position as of Q2 2022 after selling out during the quarter.
Howe & Rusling sold 35 Fulgent Genetics shares in Q2 2022, an estimated $2K.
Howe & Rusling first reported a position in Fulgent Genetics in Q4 2021 and held it in 2 quarters.
Howe & Rusling's Fulgent Genetics position peaked at $4K in Q4 2021.
262 funds tracked by Wall St. Rank held Fulgent Genetics as of Q2 2022.

Based on Howe & Rusling's 13F filing for Q2 2022, filed 15 Aug 2022.